Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | PROMISE: findings and key considerations

Annie Cowan • 18 Sep 2019
IMW 2019
Multiple Myeloma
PROMISE

Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, discusses the key considerations being made in the uptake of participants in the PROMISE trial (NCT03689595), the importance of screening high-risk individuals for myeloma precursor conditions and some preliminary findings at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Annie Cowan

1:50
Insights into the mechanisms leading to progression from MGUS and SMM to multiple myeloma
Annie Cowan • 26 Aug 2022
3:24
An update on the PANGEA model
Annie Cowan • 26 Aug 2022
0:50
Recent updates from the PROMISE study
Annie Cowan • 26 Aug 2022
1:35
An insight into MGIP and its role in the development of precursor conditions
Annie Cowan • 10 Apr 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals